Stem Cells Market Size, Share & Trends Analysis Report By Product (Adult Stem Cells, Human Embryonic Stem Cells), By Application (Regenerative Medicine), By Technology, Therapy, End-use, By Region, And Segment Forecasts, 2025 - 2030
This report can be delivered to the clients within 2 Business Days
Stem Cells Market Growth & Trends
The global stem cells market size is expected treach USD 28.89 billion by 2030, registering a CAGR of 11.41% from 2025 t2030, according ta new report by Grand View Research, Inc. Stem cells are cells that can differentiate inta variety of other cells, eventually forming organs or tissues. Many studies have been conducted over the years tassess the true potential of stem cells, leading ta variety of applications in the fields of genetic disease treatment, neurological disorders, oncology, and organ regeneration. The market is driven by the rising number of banks, growing focus on increasing therapeutic potential of these products, and extensive research for the development of regenerative medicines, among other factors.
The growing focus on regenerative therapies is fueling market expansion. iPSCs are becoming increasingly popular for the creation of customized cellular therapies, and opening up new possibilities in regenerative medicine. For instance, in September 2020, researchers from Duke-NUS and Monash University discovered the first stem cell that can aid in the treatment of placenta issues during pregnancy. The researchers devised a new method for producing induced trophoblast stem cells that can be used tgenerate placenta cells. The research will aid in the development of an in-vitrhuman placenta model and pave the way for future therapies.
Moreover, COVID-19 is acting as a catalyst for promoting the market growth. Several countries such as U.S., China, and Iran, have started conducting clinical trials using cellular therapies for treatment of COVID-19 infections. Furthermore, the use of cell therapy in the treatment of COVID-19 patients has yielded excellent results, which is fueling market expansion. In January 2020, a group of researchers in Beijing, China, tested stem cell treatment on patients tsee if it was beneficial against COVID-19. The study found that administering intravenous clinical-grade MSCs tCOVID-19 patients during first trial of treatment, improved their functional results and promoted enhanced recovery.
Increasing prevalence of cancer is one of the key factors contributing tthe growth over the forecast period. Failure of combination therapy and chemotherapy for treatment of cancer has led tthe shift in preference of physicians from such therapies tautologous and allogeneic stem cell therapy, thereby boosting the growth. Moreover, key market players and the government bodies are continuously investing in cancer research. For instance, in November 2021, California Institute for Regenerative Medicine invested USD 4 million in therapy targeting patients with acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL)
Introduction of novel technologies for the usage and adoption of cell based therapy is expected tboost the growth over the forecast period. Automation in adult stem cell & cord blood processing and storage are the key technologies expected tpositively influence the market growth. For instance, various scientists are aiming for the approval of safe, and successful treatments using stem cells in a broad range of diseases. In 2021, companies such as Biotech Cellininvested USD 75 million in an effort tmerge Artificial Intelligence technology for the development of automated stem cell manufacturing, that has the ability tregularizing access tcell treatments while aiming tbe cost effective.
On the other hand, high cost of therapy is expected thinder the market growth. For example, Biinformant, a stem cell research firm, reported that the cost of stem cell therapy ranges between USD 5,000 and USD 8,000 per patient, with some cases costing as much as USD 25,000 or more depending on the complexity of the procedure. Furthermore, restrictions on stem cell research activities have traditionally hampered embryonic stem cell growth, resulting in a meager share of the total market despite its advantages.
Stem Cells Market Report Highlights
Stem Cells Market Growth & Trends
The global stem cells market size is expected treach USD 28.89 billion by 2030, registering a CAGR of 11.41% from 2025 t2030, according ta new report by Grand View Research, Inc. Stem cells are cells that can differentiate inta variety of other cells, eventually forming organs or tissues. Many studies have been conducted over the years tassess the true potential of stem cells, leading ta variety of applications in the fields of genetic disease treatment, neurological disorders, oncology, and organ regeneration. The market is driven by the rising number of banks, growing focus on increasing therapeutic potential of these products, and extensive research for the development of regenerative medicines, among other factors.
The growing focus on regenerative therapies is fueling market expansion. iPSCs are becoming increasingly popular for the creation of customized cellular therapies, and opening up new possibilities in regenerative medicine. For instance, in September 2020, researchers from Duke-NUS and Monash University discovered the first stem cell that can aid in the treatment of placenta issues during pregnancy. The researchers devised a new method for producing induced trophoblast stem cells that can be used tgenerate placenta cells. The research will aid in the development of an in-vitrhuman placenta model and pave the way for future therapies.
Moreover, COVID-19 is acting as a catalyst for promoting the market growth. Several countries such as U.S., China, and Iran, have started conducting clinical trials using cellular therapies for treatment of COVID-19 infections. Furthermore, the use of cell therapy in the treatment of COVID-19 patients has yielded excellent results, which is fueling market expansion. In January 2020, a group of researchers in Beijing, China, tested stem cell treatment on patients tsee if it was beneficial against COVID-19. The study found that administering intravenous clinical-grade MSCs tCOVID-19 patients during first trial of treatment, improved their functional results and promoted enhanced recovery.
Increasing prevalence of cancer is one of the key factors contributing tthe growth over the forecast period. Failure of combination therapy and chemotherapy for treatment of cancer has led tthe shift in preference of physicians from such therapies tautologous and allogeneic stem cell therapy, thereby boosting the growth. Moreover, key market players and the government bodies are continuously investing in cancer research. For instance, in November 2021, California Institute for Regenerative Medicine invested USD 4 million in therapy targeting patients with acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL)
Introduction of novel technologies for the usage and adoption of cell based therapy is expected tboost the growth over the forecast period. Automation in adult stem cell & cord blood processing and storage are the key technologies expected tpositively influence the market growth. For instance, various scientists are aiming for the approval of safe, and successful treatments using stem cells in a broad range of diseases. In 2021, companies such as Biotech Cellininvested USD 75 million in an effort tmerge Artificial Intelligence technology for the development of automated stem cell manufacturing, that has the ability tregularizing access tcell treatments while aiming tbe cost effective.
On the other hand, high cost of therapy is expected thinder the market growth. For example, Biinformant, a stem cell research firm, reported that the cost of stem cell therapy ranges between USD 5,000 and USD 8,000 per patient, with some cases costing as much as USD 25,000 or more depending on the complexity of the procedure. Furthermore, restrictions on stem cell research activities have traditionally hampered embryonic stem cell growth, resulting in a meager share of the total market despite its advantages.
Stem Cells Market Report Highlights
- Adult stem cells held the largest revenue share of 70.76% of the market in 2024 as these cells dnot involve the destruction of embryos, which is the case in embryonic stem cells
- Regenerative medicine dominated the market in 2024 owing tincreasing funding by the government for the development of regenerative medicines
- The cell acquisition segment captured the highest revenue share of 33.43% of the market in 2024. The discovery of embryonic stem cells has paved the way for the development of novel treatments for several diseases
- The allogenic therapy segment captured the largest revenue share of 59.33% in 2024 with regard trevenue generation
- The pharmaceutical and biotechnology companies segment captured the largest revenue share of 54.19% in 2024
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation & Scope
1.1.1. Product Segment
1.1.2. Application Segment
1.1.3. Technology Segment
1.1.4. Therapy Segment
1.1.5. End-use Segment
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased Database
1.3.2. GVR’s Internal Database
1.3.3. Secondary Sources
1.3.4. Primary Research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List Of Secondary Sources
1.8. List Of Primary Sources
1.9. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
CHAPTER 3. MARKET VARIABLES, TRENDS, & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Ongoing Developments In Regenerative Medicine
3.2.1.2. Rising Funds For Accelerating Stem Cell Research
3.2.1.3. Growing Demand For Stem Cell Banking
3.2.1.4. Increasing Prevalence Of Genetic Disorders and Cancer
3.2.2. Market Restraint And Challenges Analysis
3.2.2.1. Ethical Concern Related To Stem Cell Research
3.2.2.2. Lack Of A Well-Defined Regulatory Framework In Certain Applications Of Stem Cell
3.3. Industry Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
CHAPTER 4. PRODUCT BUSINESS ANALYSIS
4.1. Stem Cells Market: Product Movement Analysis
4.2. Adult Stem Cells (ASCs)
4.2.1. Adult Stem Cells (ASCs) Market, 2018 - 2030 (USD Billion)
4.2.2. Hematopoietic
4.2.2.1. Hematopoietic Market, 2018 - 2030 (USD Billion)
4.2.3. Mesenchymal
4.2.3.1. Mesenchymal Market, 2018 - 2030 (USD Billion)
4.2.4. Neural
4.2.4.1. Neural Market, 2018 - 2030 (USD Billion)
4.2.5. Epithelial/Skin
4.2.5.1. Epithelial/Skin Market, 2018 - 2030 (USD Billion)
4.2.6. Others
4.2.6.1. Others Market, 2018 - 2030 (USD Billion)
4.3. Human Embryonic Stem Cells (HESCs)
4.3.1. Human Embryonic Stem Cells (HESCs) Market, 2018 - 2030 (USD Billion)
4.4. Induced Pluripotent Stem Cells (iPSCs)
4.4.1. Induced Pluripotent Stem Cells (iPSCs) Market, 2018 - 2030 (USD Billion)
4.5. Very Small Embryonic Like Stem Cells
4.5.1. Very Small Embryonic Like Stem Cells Market, 2018 - 2030 (USD Billion)
CHAPTER 5. APPLICATION BUSINESS ANALYSIS
5.1. Stem Cells Market: Application Movement Analysis
5.2. Regenerative Medicine
5.2.1. Regenerative Medicine Market, 2018 - 2030 (USD Billion)
5.2.2. Neurology
5.2.2.1. Neurology Market, 2018 - 2030 (USD Billion)
5.2.3. Orthopedics
5.2.3.1. Orthopedics Market, 2018 - 2030 (USD Billion)
5.2.4. Oncology
5.2.4.1. Oncology Market, 2018 - 2030 (USD Billion)
5.2.5. Hematology
5.2.5.1. Hematology Market, 2018 - 2030 (USD Billion)
5.2.6. Cardiovascular and Myocardial Infraction
5.2.6.1. Cardiovascular and Myocardial Infraction Market, 2018 - 2030 (USD Billion)
5.2.7. Injuries
5.2.7.1. Injuries Market, 2018 - 2030 (USD Billion)
5.2.8. Diabetes
5.2.8.1. Diabetes Market, 2018 - 2030 (USD Billion)
5.2.9. Liver Disorder
5.2.9.1. Liver Disorder Market, 2018 - 2030 (USD Billion)
5.2.10. Incontinence
5.2.10.1. Incontinence Market, 2018 - 2030 (USD Billion)
5.2.11. Others
5.2.11.1. Others Market, 2018 - 2030 (USD Billion)
5.3. Drug Discovery and Development
5.3.1. Drug Discovery and Development Market, 2018 - 2030 (USD Billion)
CHAPTER 6. TECHNOLOGY BUSINESS ANALYSIS
6.1. Stem Cells Market: Technology Movement Analysis
6.2. Cell Acquisition
6.2.1. Cell Acquisition Market, 2018 - 2030 (USD Billion)
6.2.2. Bone Marrow Harvest
6.2.2.1. Bone Marrow Harvest Market, 2018 - 2030 (USD Billion)
6.2.3. Umbilical Blood Cord
6.2.3.1. Umbilical Blood Cord Market, 2018 - 2030 (USD Billion)
6.2.4. Apheresis
6.2.4.1. Apheresis Market, 2018 - 2030 (USD Billion)
6.3. Cell Production
6.3.1. Cell Production Market, 2018 - 2030 (USD Billion)
6.3.2. Therapeutic Cloning
6.3.2.1. Therapeutic Cloning Market, 2018 - 2030 (USD Billion)
6.3.3. In-vitro Fertilization
6.3.3.1. In-vitro Fertilization Market, 2018 - 2030 (USD Billion)
6.3.4. Cell Culture
6.3.4.1. Cell Culture Market, 2018 - 2030 (USD Billion)
6.3.5. Isolation
6.3.5.1. Isolation Market, 2018 - 2030 (USD Billion)
6.4. Cryopreservation
6.4.1. Cryopreservation Market, 2018 - 2030 (USD Billion)
6.5. Expansion and Sub-Culture
6.5.1. Expansion and Sub-Culture Market, 2018 - 2030 (USD Billion)
CHAPTER 7. THERAPY BUSINESS ANALYSIS
7.1. Stem Cells Market: Therapy Movement Analysis
7.2. Autologous
7.2.1. Autologous Market, 2018 - 2030 (USD Billion)
7.3. Allogeneic
7.3.1. Allogeneic Market, 2018 - 2030 (USD Billion)
CHAPTER 8. APPLICATION BUSINESS ANALYSIS
8.1. Stem Cells Market: Application Movement Analysis
8.2. Infectious Diseases
8.2.1. Infectious Diseases Market, 2018 - 2030 (USD Billion)
8.3. Immunology
8.3.1. Immunology Market, 2018 - 2030 (USD Billion)
8.4. Oncology
8.4.1. Oncology Market, 2018 - 2030 (USD Billion)
8.5. Stem Cells
8.5.1. Stem Cells Market, 2018 - 2030 (USD Billion)
8.6. Neurobiology
8.6.1. Neurobiology Market, 2018 - 2030 (USD Billion)
8.7. Others
8.7.1. Other Applications Market, 2018 - 2030 (USD Billion)
CHAPTER 9. END USE BUSINESS ANALYSIS
9.1. Stem Cells Market: End-use Movement Analysis
9.2. Pharmaceutical and Biotechnology Companies
9.2.1. Pharmaceutical and Biotechnology Companies Market, 2018 - 2030 (USD Billion)
9.3. Hospitals & Cell Banks
9.3.1. Hospitals & Cell Banks Market, 2018 - 2030 (USD Billion)
9.4. Academic & Research Institutes
9.4.1. Academic & Research Institutes Market, 2018 - 2030 (USD Billion)
CHAPTER 10. REGIONAL BUSINESS ANALYSIS
10.1. Stem Cells Market Share By Region, 2025 & 2030
10.2. North America
10.2.1. North America Stem Cells Market, 2018 - 2030 (USD Billion)
10.2.2. U.S.
10.2.2.1. Key Country Dynamics
10.2.2.2. Target Disease Prevalence
10.2.2.3. Competitive Scenario
10.2.2.4. Regulatory Framework
10.2.2.5. U.S. Stem Cells Market, 2018 - 2030 (USD Billion)
10.2.3. Canada
10.2.3.1. Key Country Dynamics
10.2.3.2. Target Disease Prevalence
10.2.3.3. Competitive Scenario
10.2.3.4. Regulatory Framework
10.2.3.5. Canada Stem Cells Market, 2018 - 2030 (USD Billion)
10.2.4. Mexico
10.2.4.1. Key Country Dynamics
10.2.4.2. Target Disease Prevalence
10.2.4.3. Competitive Scenario
10.2.4.4. Regulatory Framework
10.2.4.5. Mexico Stem Cells Market, 2018 - 2030 (USD Billion)
10.3. Europe
10.3.1. Europe Stem Cells Market, 2018 - 2030 (USD Billion)
10.3.2. UK
10.3.2.1. Key Country Dynamics
10.3.2.2. Target Disease Prevalence
10.3.2.3. Competitive Scenario
10.3.2.4. Regulatory Framework
10.3.2.5. UK Stem Cells Market, 2018 - 2030 (USD Billion)
10.3.3. Germany
10.3.3.1. Key Country Dynamics
10.3.3.2. Target Disease Prevalence
10.3.3.3. Competitive Scenario
10.3.3.4. Regulatory Framework
10.3.3.5. Germany Stem Cells Market, 2018 - 2030 (USD Billion)
10.3.4. France
10.3.4.1. Key Country Dynamics
10.3.4.2. Target Disease Prevalence
10.3.4.3. Competitive Scenario
10.3.4.4. Regulatory Framework
10.3.4.5. France Stem Cells Market, 2018 - 2030 (USD Billion)
10.3.5. Italy
10.3.5.1. Key Country Dynamics
10.3.5.2. Target Disease Prevalence
10.3.5.3. Competitive Scenario
10.3.5.4. Regulatory Framework
10.3.5.5. Italy Stem Cells Market, 2018 - 2030 (USD Billion)
10.3.6. Spain
10.3.6.1. Key Country Dynamics
10.3.6.2. Target Disease Prevalence
10.3.6.3. Competitive Scenario
10.3.6.4. Regulatory Framework
10.3.6.5. Spain Stem Cells Market, 2018 - 2030 (USD Billion)
10.3.7. Denmark
10.3.7.1. Key Country Dynamics
10.3.7.2. Target Disease Prevalence
10.3.7.3. Competitive Scenario
10.3.7.4. Regulatory Framework
10.3.7.5. Denmark Stem Cells Market, 2018 - 2030 (USD Billion)
10.3.8. Sweden
10.3.8.1. Key Country Dynamics
10.3.8.2. Target Disease Prevalence
10.3.8.3. Competitive Scenario
10.3.8.4. Regulatory Framework
10.3.8.5. Sweden Stem Cells Market, 2018 - 2030 (USD Billion)
10.3.9. Norway
10.3.9.1. Key Country Dynamics
10.3.9.2. Target Disease Prevalence
10.3.9.3. Competitive Scenario
10.3.9.4. Regulatory Framework
10.3.9.5. Norway Stem Cells Market, 2018 - 2030 (USD Billion)
10.4. Asia Pacific
10.4.1. Asia Pacific Stem Cells Market, 2018 - 2030 (USD Billion)
10.4.2. Japan
10.4.2.1. Key Country Dynamics
10.4.2.2. Target Disease Prevalence
10.4.2.3. Competitive Scenario
10.4.2.4. Regulatory Framework
10.4.2.5. Japan Stem Cells Market, 2018 - 2030 (USD Billion)
10.4.3. China
10.4.3.1. Key Country Dynamics
10.4.3.2. Target Disease Prevalence
10.4.3.3. Competitive Scenario
10.4.3.4. Regulatory Framework
10.4.3.5. China Stem Cells Market, 2018 - 2030 (USD Billion)
10.4.4. India
10.4.4.1. Key Country Dynamics
10.4.4.2. Target Disease Prevalence
10.4.4.3. Competitive Scenario
10.4.4.4. Regulatory Framework
10.4.4.5. India Stem Cells Market, 2018 - 2030 (USD Billion)
10.4.5. Australia
10.4.5.1. Key Country Dynamics
10.4.5.2. Target Disease Prevalence
10.4.5.3. Competitive Scenario
10.4.5.4. Regulatory Framework
10.4.5.5. Australia Stem Cells Market, 2018 - 2030 (USD Billion)
10.4.6. Thailand
10.4.6.1. Key Country Dynamics
10.4.6.2. Target Disease Prevalence
10.4.6.3. Competitive Scenario
10.4.6.4. Regulatory Framework
10.4.6.5. Thailand Stem Cells Market, 2018 - 2030 (USD Billion)
10.4.7. South Korea
10.4.7.1. Key Country Dynamics
10.4.7.2. Target Disease Prevalence
10.4.7.3. Competitive Scenario
10.4.7.4. Regulatory Framework
10.4.7.5. South Korea Stem Cells Market, 2018 - 2030 (USD Billion)
10.5. Latin America
10.5.1. Latin America Stem Cells Market, 2018 - 2030 (USD Billion)
10.5.2. Brazil
10.5.2.1. Key Country Dynamics
10.5.2.2. Target Disease Prevalence
10.5.2.3. Competitive Scenario
10.5.2.4. Regulatory Framework
10.5.2.5. Brazil Stem Cells Market, 2018 - 2030 (USD Billion)
10.5.3. Argentina
10.5.3.1. Key Country Dynamics
10.5.3.2. Target Disease Prevalence
10.5.3.3. Competitive Scenario
10.5.3.4. Regulatory Framework
10.5.3.5. Argentina Stem Cells Market, 2018 - 2030 (USD Billion)
10.6. MEA
10.6.1. MEA Stem Cells Market, 2018 - 2030 (USD Billion)
10.6.2. South Africa
10.6.2.1. Key Country Dynamics
10.6.2.2. Target Disease Prevalence
10.6.2.3. Competitive Scenario
10.6.2.4. Regulatory Framework
10.6.2.5. South Africa Stem Cells Market, 2018 - 2030 (USD Billion)
10.6.3. Saudi Arabia
10.6.3.1. Key Country Dynamics
10.6.3.2. Target Disease Prevalence
10.6.3.3. Competitive Scenario
10.6.3.4. Regulatory Framework
10.6.3.5. Saudi Arabia Stem Cells Market, 2018 - 2030 (USD Billion)
10.6.4. UAE
10.6.4.1. Key Country Dynamics
10.6.4.2. Target Disease Prevalence
10.6.4.3. Competitive Scenario
10.6.4.4. Regulatory Framework
10.6.4.5. UAE Stem Cells Market, 2018 - 2030 (USD Billion)
10.6.5. Kuwait
10.6.5.1. Key Country Dynamics
10.6.5.2. Target Disease Prevalence
10.6.5.3. Competitive Scenario
10.6.5.4. Regulatory Framework
10.6.5.5. Kuwait Stem Cells Market, 2018 - 2030 (USD Billion)
CHAPTER 11. COMPETITIVE LANDSCAPE
11.1. Company Categorization
11.2. Strategy Mapping
11.3. Company Market Position Analysis, 2024
11.4. Company Profiles/Listing
11.4.1. Thermo Fisher Scientific, Inc.
11.4.1.1. Overview
11.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
11.4.1.3. Product Benchmarking
11.4.1.4. Strategic Initiatives
11.4.2. STEMCELL Technologies Inc.
11.4.2.1. Overview
11.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
11.4.2.3. Product Benchmarking
11.4.2.4. Strategic Initiatives
11.4.3. Merck KGaA
11.4.3.1. Overview
11.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
11.4.3.3. Product Benchmarking
11.4.3.4. Strategic Initiatives
11.4.4. CellGenix GmbH
11.4.4.1. Overview
11.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
11.4.4.3. Product Benchmarking
11.4.4.4. Strategic Initiatives
11.4.5. PromoCell GmbH
11.4.5.1. Overview
11.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
11.4.5.3. Product Benchmarking
11.4.5.4. Strategic Initiatives
11.4.6. Takara Holdings, Inc.
11.4.6.1. Overview
11.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
11.4.6.3. Product Benchmarking
11.4.6.4. Strategic Initiatives
11.4.7. Lonza
11.4.7.1. Overview
11.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
11.4.7.3. Product Benchmarking
11.4.7.4. Strategic Initiatives
11.4.8. Cellular Engineering Technologies
11.4.8.1. Overview
11.4.8.2. Product Benchmarking
11.4.8.3. Strategic Initiatives
11.4.9. ATCC
11.4.9.1. Overview
11.4.9.2. Product Benchmarking
11.4.9.3. Strategic Initiatives
11.4.10. AcceGen
11.4.10.1. Overview
11.4.10.2. Product Benchmarking
11.4.10.3. Strategic Initiatives
11.4.11. Cell Applications, Inc.
11.4.11.1. Overview
11.4.11.2. Product Benchmarking
11.4.11.3. Strategic Initiatives
11.4.12. Bio-Techne
11.4.12.1. Overview
11.4.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
11.4.12.3. Product Benchmarking
11.4.12.4. Strategic Initiatives
1.1. Market Segmentation & Scope
1.1.1. Product Segment
1.1.2. Application Segment
1.1.3. Technology Segment
1.1.4. Therapy Segment
1.1.5. End-use Segment
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased Database
1.3.2. GVR’s Internal Database
1.3.3. Secondary Sources
1.3.4. Primary Research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List Of Secondary Sources
1.8. List Of Primary Sources
1.9. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
CHAPTER 3. MARKET VARIABLES, TRENDS, & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Ongoing Developments In Regenerative Medicine
3.2.1.2. Rising Funds For Accelerating Stem Cell Research
3.2.1.3. Growing Demand For Stem Cell Banking
3.2.1.4. Increasing Prevalence Of Genetic Disorders and Cancer
3.2.2. Market Restraint And Challenges Analysis
3.2.2.1. Ethical Concern Related To Stem Cell Research
3.2.2.2. Lack Of A Well-Defined Regulatory Framework In Certain Applications Of Stem Cell
3.3. Industry Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
CHAPTER 4. PRODUCT BUSINESS ANALYSIS
4.1. Stem Cells Market: Product Movement Analysis
4.2. Adult Stem Cells (ASCs)
4.2.1. Adult Stem Cells (ASCs) Market, 2018 - 2030 (USD Billion)
4.2.2. Hematopoietic
4.2.2.1. Hematopoietic Market, 2018 - 2030 (USD Billion)
4.2.3. Mesenchymal
4.2.3.1. Mesenchymal Market, 2018 - 2030 (USD Billion)
4.2.4. Neural
4.2.4.1. Neural Market, 2018 - 2030 (USD Billion)
4.2.5. Epithelial/Skin
4.2.5.1. Epithelial/Skin Market, 2018 - 2030 (USD Billion)
4.2.6. Others
4.2.6.1. Others Market, 2018 - 2030 (USD Billion)
4.3. Human Embryonic Stem Cells (HESCs)
4.3.1. Human Embryonic Stem Cells (HESCs) Market, 2018 - 2030 (USD Billion)
4.4. Induced Pluripotent Stem Cells (iPSCs)
4.4.1. Induced Pluripotent Stem Cells (iPSCs) Market, 2018 - 2030 (USD Billion)
4.5. Very Small Embryonic Like Stem Cells
4.5.1. Very Small Embryonic Like Stem Cells Market, 2018 - 2030 (USD Billion)
CHAPTER 5. APPLICATION BUSINESS ANALYSIS
5.1. Stem Cells Market: Application Movement Analysis
5.2. Regenerative Medicine
5.2.1. Regenerative Medicine Market, 2018 - 2030 (USD Billion)
5.2.2. Neurology
5.2.2.1. Neurology Market, 2018 - 2030 (USD Billion)
5.2.3. Orthopedics
5.2.3.1. Orthopedics Market, 2018 - 2030 (USD Billion)
5.2.4. Oncology
5.2.4.1. Oncology Market, 2018 - 2030 (USD Billion)
5.2.5. Hematology
5.2.5.1. Hematology Market, 2018 - 2030 (USD Billion)
5.2.6. Cardiovascular and Myocardial Infraction
5.2.6.1. Cardiovascular and Myocardial Infraction Market, 2018 - 2030 (USD Billion)
5.2.7. Injuries
5.2.7.1. Injuries Market, 2018 - 2030 (USD Billion)
5.2.8. Diabetes
5.2.8.1. Diabetes Market, 2018 - 2030 (USD Billion)
5.2.9. Liver Disorder
5.2.9.1. Liver Disorder Market, 2018 - 2030 (USD Billion)
5.2.10. Incontinence
5.2.10.1. Incontinence Market, 2018 - 2030 (USD Billion)
5.2.11. Others
5.2.11.1. Others Market, 2018 - 2030 (USD Billion)
5.3. Drug Discovery and Development
5.3.1. Drug Discovery and Development Market, 2018 - 2030 (USD Billion)
CHAPTER 6. TECHNOLOGY BUSINESS ANALYSIS
6.1. Stem Cells Market: Technology Movement Analysis
6.2. Cell Acquisition
6.2.1. Cell Acquisition Market, 2018 - 2030 (USD Billion)
6.2.2. Bone Marrow Harvest
6.2.2.1. Bone Marrow Harvest Market, 2018 - 2030 (USD Billion)
6.2.3. Umbilical Blood Cord
6.2.3.1. Umbilical Blood Cord Market, 2018 - 2030 (USD Billion)
6.2.4. Apheresis
6.2.4.1. Apheresis Market, 2018 - 2030 (USD Billion)
6.3. Cell Production
6.3.1. Cell Production Market, 2018 - 2030 (USD Billion)
6.3.2. Therapeutic Cloning
6.3.2.1. Therapeutic Cloning Market, 2018 - 2030 (USD Billion)
6.3.3. In-vitro Fertilization
6.3.3.1. In-vitro Fertilization Market, 2018 - 2030 (USD Billion)
6.3.4. Cell Culture
6.3.4.1. Cell Culture Market, 2018 - 2030 (USD Billion)
6.3.5. Isolation
6.3.5.1. Isolation Market, 2018 - 2030 (USD Billion)
6.4. Cryopreservation
6.4.1. Cryopreservation Market, 2018 - 2030 (USD Billion)
6.5. Expansion and Sub-Culture
6.5.1. Expansion and Sub-Culture Market, 2018 - 2030 (USD Billion)
CHAPTER 7. THERAPY BUSINESS ANALYSIS
7.1. Stem Cells Market: Therapy Movement Analysis
7.2. Autologous
7.2.1. Autologous Market, 2018 - 2030 (USD Billion)
7.3. Allogeneic
7.3.1. Allogeneic Market, 2018 - 2030 (USD Billion)
CHAPTER 8. APPLICATION BUSINESS ANALYSIS
8.1. Stem Cells Market: Application Movement Analysis
8.2. Infectious Diseases
8.2.1. Infectious Diseases Market, 2018 - 2030 (USD Billion)
8.3. Immunology
8.3.1. Immunology Market, 2018 - 2030 (USD Billion)
8.4. Oncology
8.4.1. Oncology Market, 2018 - 2030 (USD Billion)
8.5. Stem Cells
8.5.1. Stem Cells Market, 2018 - 2030 (USD Billion)
8.6. Neurobiology
8.6.1. Neurobiology Market, 2018 - 2030 (USD Billion)
8.7. Others
8.7.1. Other Applications Market, 2018 - 2030 (USD Billion)
CHAPTER 9. END USE BUSINESS ANALYSIS
9.1. Stem Cells Market: End-use Movement Analysis
9.2. Pharmaceutical and Biotechnology Companies
9.2.1. Pharmaceutical and Biotechnology Companies Market, 2018 - 2030 (USD Billion)
9.3. Hospitals & Cell Banks
9.3.1. Hospitals & Cell Banks Market, 2018 - 2030 (USD Billion)
9.4. Academic & Research Institutes
9.4.1. Academic & Research Institutes Market, 2018 - 2030 (USD Billion)
CHAPTER 10. REGIONAL BUSINESS ANALYSIS
10.1. Stem Cells Market Share By Region, 2025 & 2030
10.2. North America
10.2.1. North America Stem Cells Market, 2018 - 2030 (USD Billion)
10.2.2. U.S.
10.2.2.1. Key Country Dynamics
10.2.2.2. Target Disease Prevalence
10.2.2.3. Competitive Scenario
10.2.2.4. Regulatory Framework
10.2.2.5. U.S. Stem Cells Market, 2018 - 2030 (USD Billion)
10.2.3. Canada
10.2.3.1. Key Country Dynamics
10.2.3.2. Target Disease Prevalence
10.2.3.3. Competitive Scenario
10.2.3.4. Regulatory Framework
10.2.3.5. Canada Stem Cells Market, 2018 - 2030 (USD Billion)
10.2.4. Mexico
10.2.4.1. Key Country Dynamics
10.2.4.2. Target Disease Prevalence
10.2.4.3. Competitive Scenario
10.2.4.4. Regulatory Framework
10.2.4.5. Mexico Stem Cells Market, 2018 - 2030 (USD Billion)
10.3. Europe
10.3.1. Europe Stem Cells Market, 2018 - 2030 (USD Billion)
10.3.2. UK
10.3.2.1. Key Country Dynamics
10.3.2.2. Target Disease Prevalence
10.3.2.3. Competitive Scenario
10.3.2.4. Regulatory Framework
10.3.2.5. UK Stem Cells Market, 2018 - 2030 (USD Billion)
10.3.3. Germany
10.3.3.1. Key Country Dynamics
10.3.3.2. Target Disease Prevalence
10.3.3.3. Competitive Scenario
10.3.3.4. Regulatory Framework
10.3.3.5. Germany Stem Cells Market, 2018 - 2030 (USD Billion)
10.3.4. France
10.3.4.1. Key Country Dynamics
10.3.4.2. Target Disease Prevalence
10.3.4.3. Competitive Scenario
10.3.4.4. Regulatory Framework
10.3.4.5. France Stem Cells Market, 2018 - 2030 (USD Billion)
10.3.5. Italy
10.3.5.1. Key Country Dynamics
10.3.5.2. Target Disease Prevalence
10.3.5.3. Competitive Scenario
10.3.5.4. Regulatory Framework
10.3.5.5. Italy Stem Cells Market, 2018 - 2030 (USD Billion)
10.3.6. Spain
10.3.6.1. Key Country Dynamics
10.3.6.2. Target Disease Prevalence
10.3.6.3. Competitive Scenario
10.3.6.4. Regulatory Framework
10.3.6.5. Spain Stem Cells Market, 2018 - 2030 (USD Billion)
10.3.7. Denmark
10.3.7.1. Key Country Dynamics
10.3.7.2. Target Disease Prevalence
10.3.7.3. Competitive Scenario
10.3.7.4. Regulatory Framework
10.3.7.5. Denmark Stem Cells Market, 2018 - 2030 (USD Billion)
10.3.8. Sweden
10.3.8.1. Key Country Dynamics
10.3.8.2. Target Disease Prevalence
10.3.8.3. Competitive Scenario
10.3.8.4. Regulatory Framework
10.3.8.5. Sweden Stem Cells Market, 2018 - 2030 (USD Billion)
10.3.9. Norway
10.3.9.1. Key Country Dynamics
10.3.9.2. Target Disease Prevalence
10.3.9.3. Competitive Scenario
10.3.9.4. Regulatory Framework
10.3.9.5. Norway Stem Cells Market, 2018 - 2030 (USD Billion)
10.4. Asia Pacific
10.4.1. Asia Pacific Stem Cells Market, 2018 - 2030 (USD Billion)
10.4.2. Japan
10.4.2.1. Key Country Dynamics
10.4.2.2. Target Disease Prevalence
10.4.2.3. Competitive Scenario
10.4.2.4. Regulatory Framework
10.4.2.5. Japan Stem Cells Market, 2018 - 2030 (USD Billion)
10.4.3. China
10.4.3.1. Key Country Dynamics
10.4.3.2. Target Disease Prevalence
10.4.3.3. Competitive Scenario
10.4.3.4. Regulatory Framework
10.4.3.5. China Stem Cells Market, 2018 - 2030 (USD Billion)
10.4.4. India
10.4.4.1. Key Country Dynamics
10.4.4.2. Target Disease Prevalence
10.4.4.3. Competitive Scenario
10.4.4.4. Regulatory Framework
10.4.4.5. India Stem Cells Market, 2018 - 2030 (USD Billion)
10.4.5. Australia
10.4.5.1. Key Country Dynamics
10.4.5.2. Target Disease Prevalence
10.4.5.3. Competitive Scenario
10.4.5.4. Regulatory Framework
10.4.5.5. Australia Stem Cells Market, 2018 - 2030 (USD Billion)
10.4.6. Thailand
10.4.6.1. Key Country Dynamics
10.4.6.2. Target Disease Prevalence
10.4.6.3. Competitive Scenario
10.4.6.4. Regulatory Framework
10.4.6.5. Thailand Stem Cells Market, 2018 - 2030 (USD Billion)
10.4.7. South Korea
10.4.7.1. Key Country Dynamics
10.4.7.2. Target Disease Prevalence
10.4.7.3. Competitive Scenario
10.4.7.4. Regulatory Framework
10.4.7.5. South Korea Stem Cells Market, 2018 - 2030 (USD Billion)
10.5. Latin America
10.5.1. Latin America Stem Cells Market, 2018 - 2030 (USD Billion)
10.5.2. Brazil
10.5.2.1. Key Country Dynamics
10.5.2.2. Target Disease Prevalence
10.5.2.3. Competitive Scenario
10.5.2.4. Regulatory Framework
10.5.2.5. Brazil Stem Cells Market, 2018 - 2030 (USD Billion)
10.5.3. Argentina
10.5.3.1. Key Country Dynamics
10.5.3.2. Target Disease Prevalence
10.5.3.3. Competitive Scenario
10.5.3.4. Regulatory Framework
10.5.3.5. Argentina Stem Cells Market, 2018 - 2030 (USD Billion)
10.6. MEA
10.6.1. MEA Stem Cells Market, 2018 - 2030 (USD Billion)
10.6.2. South Africa
10.6.2.1. Key Country Dynamics
10.6.2.2. Target Disease Prevalence
10.6.2.3. Competitive Scenario
10.6.2.4. Regulatory Framework
10.6.2.5. South Africa Stem Cells Market, 2018 - 2030 (USD Billion)
10.6.3. Saudi Arabia
10.6.3.1. Key Country Dynamics
10.6.3.2. Target Disease Prevalence
10.6.3.3. Competitive Scenario
10.6.3.4. Regulatory Framework
10.6.3.5. Saudi Arabia Stem Cells Market, 2018 - 2030 (USD Billion)
10.6.4. UAE
10.6.4.1. Key Country Dynamics
10.6.4.2. Target Disease Prevalence
10.6.4.3. Competitive Scenario
10.6.4.4. Regulatory Framework
10.6.4.5. UAE Stem Cells Market, 2018 - 2030 (USD Billion)
10.6.5. Kuwait
10.6.5.1. Key Country Dynamics
10.6.5.2. Target Disease Prevalence
10.6.5.3. Competitive Scenario
10.6.5.4. Regulatory Framework
10.6.5.5. Kuwait Stem Cells Market, 2018 - 2030 (USD Billion)
CHAPTER 11. COMPETITIVE LANDSCAPE
11.1. Company Categorization
11.2. Strategy Mapping
11.3. Company Market Position Analysis, 2024
11.4. Company Profiles/Listing
11.4.1. Thermo Fisher Scientific, Inc.
11.4.1.1. Overview
11.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
11.4.1.3. Product Benchmarking
11.4.1.4. Strategic Initiatives
11.4.2. STEMCELL Technologies Inc.
11.4.2.1. Overview
11.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
11.4.2.3. Product Benchmarking
11.4.2.4. Strategic Initiatives
11.4.3. Merck KGaA
11.4.3.1. Overview
11.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
11.4.3.3. Product Benchmarking
11.4.3.4. Strategic Initiatives
11.4.4. CellGenix GmbH
11.4.4.1. Overview
11.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
11.4.4.3. Product Benchmarking
11.4.4.4. Strategic Initiatives
11.4.5. PromoCell GmbH
11.4.5.1. Overview
11.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
11.4.5.3. Product Benchmarking
11.4.5.4. Strategic Initiatives
11.4.6. Takara Holdings, Inc.
11.4.6.1. Overview
11.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
11.4.6.3. Product Benchmarking
11.4.6.4. Strategic Initiatives
11.4.7. Lonza
11.4.7.1. Overview
11.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
11.4.7.3. Product Benchmarking
11.4.7.4. Strategic Initiatives
11.4.8. Cellular Engineering Technologies
11.4.8.1. Overview
11.4.8.2. Product Benchmarking
11.4.8.3. Strategic Initiatives
11.4.9. ATCC
11.4.9.1. Overview
11.4.9.2. Product Benchmarking
11.4.9.3. Strategic Initiatives
11.4.10. AcceGen
11.4.10.1. Overview
11.4.10.2. Product Benchmarking
11.4.10.3. Strategic Initiatives
11.4.11. Cell Applications, Inc.
11.4.11.1. Overview
11.4.11.2. Product Benchmarking
11.4.11.3. Strategic Initiatives
11.4.12. Bio-Techne
11.4.12.1. Overview
11.4.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
11.4.12.3. Product Benchmarking
11.4.12.4. Strategic Initiatives
